目次

Chapter 1: Overview: B. Burtness and E. GolemisChapter 2: HER inhibition in HNC: E. Golemis and B. BurtnessChapter 3: MET: T Beck, Fox Chase Cancer CenterChapter 4: PI3K/mTOR/AMPK: C. Chung, Moffit Cancer CenterChapter 5: Jak/STAT: J.R. Grandis, UCSFChapter 6: TGFb: Neiman and Wang, University of ColoradoChapter 7: Wnt and catenin Signaling: MA Kukurusinska, Boston UniversityChapter 8: P53/p63/p73: B. BurtnessChapter 9: DNA damage: R. Bindra, Yale UniversityChapter 10: APOBEC Proteins: K.S. Anderson, Yale UniversityChapter 11:  Hypoxia, including HIF1: Q. Le, Stanford UniversityChapter 12:  VEGF/Angiogenesis and Antiangiogenic Therapy:  A Argiris, Thomas Jefferson UniversityChapter 13: Sequencing/genomic insights: J.Myers, MD AndersonChapter 14:  Gene expression, Methylation, and histones: R.Mehra, A.Andrews, S.Peri, Fox Chase Cancer Center and A.Bhatia, Yale UniversityChapter 15: Inflammation:  Carter Van Waes, NIHChapter 16:Immunotherapy: Ferris and Baumann, UPMCChapter 17: FAK/Integrin pathway inhibitors: Nils Cordes, DresdenChapter 18: Targeting cell cycle controls:  E.GolemisChapter 19: Head and neck cancer stem cells:  L.Bourguignon, UCSFChapter 20: Non-coding RNAs:  C.Punyadeera, Queensland UniversityChapter 21:  Epidemiology of HPV: Ragin and Lui, Fox Chase Cancer CenterChapter 22: DNA damage in HPV-positive SCCHN: WG Yarbrough, Yale UniversityChapter 23: Treatment paradigms in HPV-positive SCCHN: A Cmelak, Vanderbilt University